Embecta To Discontinue Insulin Patch Pump Program And Initiate An Organizational Restructuring Plan
Embecta To Discontinue Insulin Patch Pump Program And Initiate An Organizational Restructuring Plan
Embecta計劃停止胰島素貼片泵項目，並啓動組織重組計劃
- The Company currently expects to incur total pre-tax charges of between $35 million and $45 million in fiscal year 2025 related to the restructuring plan, consisting of between $25 million and $30 million in pre-tax, cash charges for planned workforce reductions and other associated costs from the discontinuation of the patch pump program, and between $10 million and $15 million in pre-tax, non-cash charges for asset impairments and write-offs. Note, these preliminary estimates may be revised following the completion of the ongoing analysis of the expected additional pre-tax non-cash charges associated with the implementation of the restructuring plan.
- The Company expects the restructuring plan to be substantially complete during the first half of fiscal year 2025 and expects the discontinuation of the patch pump program and organizational restructuring plan to generate annualized pre-tax cost savings of between $60 million and $65 million. Given the organizational restructuring plan, the Company has decided to postpone the previously announced Analyst & Investor Day to Spring 2025.
- 公司當前預計，相關重組計劃將使2025財年產生總計稅前費用在3500萬美元至4500萬美元之間，其中包括打算裁員和因停止使用貼片泵項目以及相關成本而產生的現金費用，在2500萬美元至3000萬美元之間；而非現金費用將在1000萬美元至1500萬美元之間，用於資產減值和沖銷。請注意，這些初步估計可能在完成對與重組計劃實施相關的預期額外非現金費用的持續分析後進行修訂。
- 公司預計重組計劃將在2025財年上半年基本完成，並預計停止使用貼片泵項目和組織重組計劃將帶來年化稅前節省成本在6000萬美元至6500萬美元之間。鑑於組織重組計劃，公司決定推遲之前宣佈的分析師和投資者日至2025年春季。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間